RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the “TSX”) to extend the exercise period of a total of 4,546,000 outstanding common share purchase warrants (the “Warrants”), all of which are held by arm’s length parties. The Warrants were issued pursuant to a private placement of the Company completed on November 1, 2013, and represent approximately 4.4% of the Company’s issued and outstanding common shares.
20181016-HBP-Press-Release-Extends-Period-to-Exercise-Warrants-FINAL.pdf